Sarepta Therapeutics (NASDAQ: SRPT) has been steadily building up its gene therapy capabilities for a few years now, and it took two more steps forward on that front this morning. First, it exercised an option to buy gene therapy startup Myonexus Therapeutics for $165 million. And then it disclosed early human results from the first program to come from the deal, a potential treatment for a form of Limb-Girdle Muscular Dystrophy (LGMD), a progressive, deadly genetic disease with no available treatments.
Sarepta first announced a partnership with Myonexus, a spinout of Nationwide Children’s Hospital in Columbus, OH, in May 2018…. Read more »